|
|
News Headlines Materials & Formulation
|
|
|
|
Strong sales at Teva's API division
07-May-2008 - Teva's sales of active pharmaceutical ingredients (APIs) for the first quarter of 2008 rose by 51 per cent on the previous years figure, taking to total to $510m.
AM Technology's continuous reactor a 'beautiful solution'
05-May-2008 - UK-based AM Technology has developed the Coflore Agitated Cell Reactor (ACR) which it claims offers significant advantages over traditional continuous stirred tank reactors.
Prolient takes major step forward in BSA production
30-Apr-2008 - US-based Prolient has improved its "closed loop" bovine serum albumin (BSA) manufacturing process, in what it describes as a "major step forward".
Kyowa Hakko biochemicals prosper on back of acquisitions
30-Apr-2008 - Japan-based Kyowa Hakko's biochemical segment has experienced 135.6 per cent growth taking the departments operating income for the 2007 financial year to $92.4m.
Unigene launches joint venture with Chinese state
28-Apr-2008 - US drugmaker Unigene has begun construction of new facilities in China as part of its joint venture with a state-owned Chinese pharmaceutical company to establish research, development and manufacturing capacities in the nation.
Biocatalyst specialist Codexis files IPO
23-Apr-2008 - US-based biotech company Codexis has filed an initial public offering (IPO), the first step towards becoming a public company.
Novozymes licenses fast DNA engineering technology
22-Apr-2008 - Germany-based Gene Bridges has licensed its Red/ET Recombineering technology to Novozymes for genetically engineering recombinant micro-organisms for use in industrial applications.
Collette to show "revolutionary" granulation machine
21-Apr-2008 - GEA Pharma Systems' Collette unit will present Consigma, its new continuous high shear granulation and drying system, at the Interpack exhibition in Düsseldorf later this month.
AIR pullout claims 500 jobs at Lilly
17-Apr-2008 - Eli Lilly plans to cut 500 jobs, mainly in manufacturing, as it attempts to restructure its operations to mitigate against the losses from inhaled insulin.
FDA suspects heparin contamination due to fraud
17-Apr-2008 - The US Food and Drug Administration (FDA) believes that the contamination of Baxter's blood thinner heparin, which has been linked to 62 deaths in the US, may have been due to the deliberate replacement of some ingredients with cheaper alternatives.
|
|
|
|
|
